.Alnylam is actually putting on hold even further progression of a clinical-stage RNAi curative deve...
.Takeda has actually quit (PDF) a phase 2 trial of danavorexton because of sluggish enrollment, noti...
.Compass Pathways' journey to period 3 psychedelic anxiety information is taking much longer than an...
.After antibody-drug conjugate (ADC) professional Seagen was sold to Pfizer last year for a massive ...
.On the heels of a stage 3 win that neglected to thrill financiers, Ironwood Pharmaceuticals is back...
.Don't quit Monte Rosa Therapeutics currently. The Boston-based biotech is having a ball after signi...
.Welcome to recently's Chutes & Ladders, our roundup of notable leadership hirings, firings and a...
.Celebrating his business's upsized going public (IPO), Septerna chief executive officer Jeffrey Fin...
.AbbVie has gone back to the source of its antipsychotic powerhouse Vraylar seeking one more smash h...
.GenSight Biologics is full weeks off of losing loan. Once more. The biotech merely has enough cash ...